Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "AP"

6951 News Found

Zydus receives final approval from USFDA for Isotretinoin Capsules USP
Drug Approval | May 24, 2025

Zydus receives final approval from USFDA for Isotretinoin Capsules USP

Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne


Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP
Drug Approval | May 24, 2025

Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP

Allopurinol is used to prevent or lower high uric acid levels in the blood


Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP
Drug Approval | May 24, 2025

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP

Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin


Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr
News | May 18, 2025

Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr

Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025


Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection
Drug Approval | May 14, 2025

Caplin Steriles gets USFDA approval for Haloperidol Decanoate Injection

Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy


LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa
News | May 13, 2025

LG Chem sets sights on global market with launch of diabetes combination therapy Zemidapa

Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership


Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity
News | May 13, 2025

Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity

Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease